Establishment of immortalized normal salivary glands epithelial cells and regeneration of salivary gland for post-irradiation

永生化正常唾液腺上皮细胞的建立及辐照后唾液腺的再生

基本信息

  • 批准号:
    19592331
  • 负责人:
  • 金额:
    $ 2.75万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2007
  • 资助国家:
    日本
  • 起止时间:
    2007 至 2009
  • 项目状态:
    已结题

项目摘要

In individualized countries the majority of patients with head and neck cancer are treated with radiation therapy. Exposure of the major salivary glands to the ionizing radiation induced fibrosis fatty degeneration of the gland tissue and atrophy of the saliva-producting acinar cells. Saliva production is decreased in correlation with the irradiation dose and the gland volume exposed to the radiation field. Current management of radiation induced xerostomia includes the administration of saliva substitutes and sialogogues. Based on the principles of tissue engineering, we investigated the feasibility of engineering human salivary gland tissue for the treatment of salivary gland hypofunction. There are two major mechanisms that cause the limited life span of primary culture cells. One is the telomere-based senescene, and the other is telomere-independent senescene, which is thought to be controlled by the Rb/p16 and p53 pathways. To elucidate the regeneration of normal salivary gland cell, we established immortalized human salivary gland epithelial cell (hSalEC)s transduced with non-viral human gene (mutant Cdk4, cyclin D1, and hTERT). By Cdk4 and cyclinD1 transduction in combination with hTERT, we here established novel hSalEC cell line. This is a first report of successful establishment of hSalEC cells immortalization.
在个别国家,大多数头颈癌患者接受放射治疗。大唾液腺暴露于电离辐射引起腺体组织纤维化、脂肪变性和分泌唾液的腺泡细胞萎缩。唾液分泌减少与辐射剂量和暴露于辐射场的腺体体积相关。目前的管理辐射引起的口干症包括管理唾液替代品和唾液。本研究以组织工程学原理为基础,探讨组织工程化人涎腺组织用于治疗涎腺功能减退症的可行性。有两种主要机制导致原代培养细胞的寿命有限。一种是基于端粒的衰老,另一种是端粒非依赖性衰老,这被认为是由Rb/p16和p53通路控制的。为了研究正常涎腺细胞的再生机制,我们建立了转人非病毒基因(突变型Cdk 4、cyclin D1和hTERT)的永生化人涎腺上皮细胞(hSalEC)。通过Cdk 4和cyclinD 1的联合转导和hTERT的作用,我们建立了一种新的hSalEC细胞系。这是首次成功建立hSalEC细胞永生化的报道。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NOGUCHI Kazuma其他文献

NOGUCHI Kazuma的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NOGUCHI Kazuma', 18)}}的其他基金

Mechanism of acquired resistance and genome evolution treated with anti-cancer drug against oral cancer
抗癌药物治疗口腔癌的获得性耐药和基因组进化机制
  • 批准号:
    16K11737
  • 财政年份:
    2016
  • 资助金额:
    $ 2.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular analysis of oral carcinogenesis with in vitro multistepcarcinogenesis model
体外多步致癌模型对口腔癌发生的分子分析
  • 批准号:
    22592249
  • 财政年份:
    2010
  • 资助金额:
    $ 2.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-Enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI)
动态对比增强 MRI 的定量成像生物标志物前瞻性验证作为放射治疗后口腔牙齿损伤的指标 (QI-ProVE-MRI)
  • 批准号:
    10668570
  • 财政年份:
    2023
  • 资助金额:
    $ 2.75万
  • 项目类别:
Molecular Strategies to Widen the Therapeutic Index of Radiotherapy
扩大放射治疗治疗指数的分子策略
  • 批准号:
    10334198
  • 财政年份:
    2022
  • 资助金额:
    $ 2.75万
  • 项目类别:
A Multifaceted Radiomics Model to Predict Cervical Lymph Node Metastasis for Involved Nodal Radiation Therapy
预测涉及淋巴结放射治疗的颈部淋巴结转移的多方面放射组学模型
  • 批准号:
    10654048
  • 财政年份:
    2022
  • 资助金额:
    $ 2.75万
  • 项目类别:
Project 2: ALDH3A1 Activation for Radioprotection of Salivary Glands and Other Head and Neck Epithelial Tissues
项目2:ALDH3A1激活对唾液腺和其他头颈上皮组织的辐射防护
  • 批准号:
    10334200
  • 财政年份:
    2022
  • 资助金额:
    $ 2.75万
  • 项目类别:
PSMAi-PARPi combination agents for the targeted Auger and alpha therapy of metastatic castration-resistant prostate cancer
PSMAi-PARPi 组合药物用于转移性去势抵抗性前列腺癌的靶向 Auger 和 alpha 疗法
  • 批准号:
    10508057
  • 财政年份:
    2022
  • 资助金额:
    $ 2.75万
  • 项目类别:
Molecular Strategies to Widen the Therapeutic Index of Radiotherapy
扩大放射治疗治疗指数的分子策略
  • 批准号:
    10707879
  • 财政年份:
    2022
  • 资助金额:
    $ 2.75万
  • 项目类别:
Project 2: ALDH3A1 Activation for Radioprotection of Salivary Glands and Other Head and Neck Epithelial Tissues
项目2:ALDH3A1激活对唾液腺和其他头颈上皮组织的辐射防护
  • 批准号:
    10707889
  • 财政年份:
    2022
  • 资助金额:
    $ 2.75万
  • 项目类别:
Therapeutic mechanisms of iPSC-MSC derived extracellular vesicles on dry mouth caused by Sjorgren's syndrome or radiotherapy
iPSC-MSC来源的细胞外囊泡治疗干燥综合征或放疗引起的口干的机制
  • 批准号:
    10701307
  • 财政年份:
    2022
  • 资助金额:
    $ 2.75万
  • 项目类别:
Diversity Supplement: Radiation-specific Automated Dental Dose Distributions via Machine-learning based Mapping for Accurate Predictions of (Peri)odontal Problems (RADMAP)
多样性补充:通过基于机器学习的映射实现特定辐射的自动牙科剂量分布,以准确预测(牙周)牙周问题 (RADMAP)
  • 批准号:
    10602003
  • 财政年份:
    2022
  • 资助金额:
    $ 2.75万
  • 项目类别:
A System for Xerostomia Risk Classification after Head & Neck Cancer Radiotherapy
头后口干症风险分类系统
  • 批准号:
    10410192
  • 财政年份:
    2021
  • 资助金额:
    $ 2.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了